Novonesis (novozymes)-ADRNVZMY
13F holders, Q2 2024 (June 30)6holders −3
0new positions
3sold out
$61.09avg. 13F price*
At the end of Q2 2024, 6 institutions reported holding Novonesis (novozymes)-ADR (NVZMY) in their 13F filings, down 3 from Q1 2024. 0 opened new positions and 3 sold out. The largest holders were Rhumbline Advisers ($527K), Mar Vista Investment Partners LLC ($347K) and Boston Common Asset Management, LLC ($282K).
- Company
- Novonesis (novozymes)-ADR
- CUSIP
- 670108109
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 3 | $49K |
All 13F filers, Q1 2024 → Q2 2024: 1,530 shares bought and 1,758 shares sold, net −228 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 6 holders
| Rhumbline Advisers | 0.00% | Add +3.9% | 8,632 | $527K |
| Mar Vista Investment Partners LLC | 0.02% | Add +25.3% | 5,680 | $347K |
| Boston Common Asset Management, LLC | 0.01% | Reduce -13.8% | 4,613 | $282K |
| S&co Inc. | 0.02% | No change | 4,500 | $275K |
| PNC Financial Services Group, Inc. | 0.00% | Reduce -6.0% | 2,113 | $129K |
| GAMMA Investing LLC | 0.01% | Add +8.2% | 749 | $46K |
"% of holder's portfolio" is NVZMY's weight in each manager's 13F, not the share of Novonesis (novozymes)-ADR the manager owns.